Reuters logo
BRIEF-Erytech Pharma's complete results demonstrate statistically improvement in overall survival and progression-free survival ‍​
September 8, 2017 / 5:38 AM / 2 months ago

BRIEF-Erytech Pharma's complete results demonstrate statistically improvement in overall survival and progression-free survival ‍​

Sept 8 (Reuters) - ERYTECH PHARMA SA:

* COMPLETE DATA DEMONSTRATE A STATISTICALLY SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL ‍​

* COMPLETE RESULTS FOR PHASE 2B STUDY WITH ERYASPASE IN COMBINATION WITH CHEMOTHERAPY IN SECOND-LINE TREATMENT OF METASTATIC PANCREATIC CANCER‍​

* A MEETING WITH THE US FDA IS SCHEDULED TO DISCUSS THE DESIGN OF A PHASE 3 STUDY‍​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below